Evercore ISI analyst Umer Raffat maintained a Hold rating on Eli Lilly & Co (LLY – Research Report) yesterday. The company’s shares closed ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

Eli Lilly recently updated Q4 revenue guidance, and sales are expected to come in lower than previously anticipated. While this could suggest the company is experiencing sluggish or plateauing ...

We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Unfortunately, the good times didn't last very long. The stock peaked last October and was down by more than 21% when ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.

Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $973 from $995 and keeps a Buy rating on the shares. The firm is updating its global biopharma coverage forecasts ahead of Q4 ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's largest healthcare company, with a market cap that topped $860 billion at one ...